Patients with myeloma whose tumor immune microenvironments had a more diverse baseline T-cell repertoire, fewer markers of immune cell exhaustion, and distinct changes to immune cell populations were more likely to have longer ...
Aug 30, 2022
0
42
Breast cancer is categorized into three major subtypes: hormone receptor-positive, HER2-positive, and triple-negative. Although there are targeted therapeutic approaches for the first two, there are limited options for triple ...
Aug 29, 2022
0
37
In the war against cancer, one of the most critical battles is waged on a cellular level as T cells from the immune system are altered in the lab to attack cancer cells. This form of immunotherapy, called chimeric antigen ...
Aug 25, 2022
0
69
New research has revealed how the tau protein, a critical element in the formation of Alzheimer's disease, is also involved in normal learning processes in the healthy brain—potentially providing a focal point for future ...
Aug 23, 2022
0
22
In the aftermath of a stroke or TBI, a group of amino acids that typically support brain function contribute significantly to the brain destruction that can follow both these injuries, scientists report.
Aug 23, 2022
0
83
The world's smallest arms race could be happening right now in your gut.
Aug 19, 2022
0
18
UT Southwestern researchers have identified a molecular pathway responsible for the spread of glioblastoma to surrounding tissue in the brain, as well as an existing drug that curbed tumor growth in animal models. The findings, ...
Aug 10, 2022
0
1109
Research from the laboratories of Dr. André Veillette, Director of Research in Molecular Oncology at the Montreal Clinical Research Institute (IRCM) and Professor and Researcher in the Department of Medicine at the Université ...
Aug 8, 2022
0
65
Like the hardiest weed, glioblastoma almost always springs back—usually within months after a patient's initial brain tumor is surgically removed. That is why survival rates for this cancer are just 25 percent at one year ...
Aug 8, 2022
0
1770
Scientists at St. Jude Children's Research Hospital are improving chimeric antigen receptor (CAR) T-cell therapy. Their new simplified approach selected for an advantageous T-cell type and showed promise in the lab against ...
Aug 5, 2022
0
39
